A Comparison of Frailty Measures at Listing to Predict Outcomes After Lung Transplantation

ConclusionsSarcopenia is prevalent in LTx patients. Neither sarcopenia nor 6MWD predicted mortality or short-term outcomes after LTx. This is in contrast to albumin levels, which were inversely associated with survival and complications. Albumin shows promise as an important predictor of mortality and short-term outcomes after LTx.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

Publication date: 21 January 2020Source: Cell Reports, Volume 30, Issue 3Author(s): Carmit Hillel-Karniel, Chava Rosen, Irit Milman-Krentsis, Ran Orgad, Esther Bachar-Lustig, Elias Shezen, Yair ReisnerSummaryInduction of lung regeneration by transplantation of lung progenitor cells is a critical preclinical challenge. Recently, we demonstrated that robust lung regeneration can be achieved if the endogenous stem cell niches in the recipient’s lung are vacated by sub-lethal pre-conditioning. However, overcoming MHC barriers is an additional requirement for clinical application of this attractive approach. We demonstrat...
Source: Cell Reports - Category: Cytology Source Type: research
We describe a case of successful combined management of BPAF using both bronchial and pulmonary stent placement.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the non-invasive French risk assessment approach (number of low-risk criteria based on the ESC/ERS guidelines) and REVEAL 2.0 risk calculator. The prognostic and predictive value of these methods for morbidity/mortality was evaluated in the predominantly prevalent population of GRIPHON, the largest randomized controlled trial in PAH.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Despite advances in drug development, life expectancy in idiapathic pulmonary arterial hypertension (IPAH) remains unacceptable. Contemporary IPAH characterization is based on criteria that may not adequately capture disease heterogeneity and may be proposed as a possible explanation for why patient's outcome is still unfavorable.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Patients with cardiogenic shock (CS) needing temporary circulatory support (TCS) have poor survival after durable ventricular assist device (dVAD). We aimed to characterize post-dVAD adverse event burden and survival in those requiring pre-operative TCS.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Lung transplantation (LTx) offers a survival benefit for patients with end-stage lung disease. When suitable donors are identified, centers must accept or decline the offer for a matched candidate on their waitlist. The degree to which variability in per-center offer acceptance practices impacts candidate survival is not established. The purpose of this study was to determine the degree of variability in per-center rates of LTX offer acceptance, and to ascertain the associated contribution to observed differences in per-center waitlist mortality.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
In this study, we determined whether symptomatic respiratory viral infections in post-lung transplantation induce circulating exosomes that contain lung-associated self-antigens, and to assess whether these exosomes activate immune responses to self-antigens.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Pre-Clinical Science Source Type: research
Ambrisentan is effective in Group 1 pulmonary arterial hypertension (PAH). Although portopulmonary hypertension (PoPH) is a subset of Group 1 PAH, few clinical trials testing PAH therapies enrolled PoPH patients. We aimed to evaluate the efficacy and safety of ambrisentan in PoPH.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Cytomegalovirus (CMV) infection is the most prevalent viral infection in heart transplant recipients. Current strategies for the prevention of CMV infection after heart transplantation include either universal prophylaxis (ranging from 100 to 200 days) or preemptive therapy1,2. Since the international consensus on CMV prophylaxis and treatment2 lacks definite recommendations on optimal CMV infection prevention and the duration of prophylaxis, these are subject to significant intercenter variability.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Research Correspondence - clinical Source Type: research
In this study, we assessed the efficacy and safety of DOACs compared to warfarin after HTx.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Research Correspondence Source Type: research
More News: Cardiovascular & Thoracic Surgery | Lung Transplant | Transplants